Piramal Pharma Limited has informed the Exchange regarding 'Sustainability Report for the financial year 2024-25'.
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Piramal Pharma has submitted its Sustainability Report for FY2024-25 to the exchanges, covering the period April 1, 2024 to March 31, 2025. The report highlights revenue of ₹9,151.18 crore (up 11.99% YoY), net profit of ₹91.13 crore (a 5x jump from ₹17.82 crore last year), and an EBITDA margin of 17.26%. Market capitalisation rose 75% to ₹29,796 crore while net debt to EBITDA improved from 5.6x to 2.7x. On ESG, the company reported 3% lower GHG emissions, a 7.8% rise in renewable energy share, zero hazardous waste to landfill, and 20% women in its global workforce. It scored 55/100 on the S&P Global ESG assessment and earned a Bronze medal from EcoVadis with a 65/100 score.
This is a routine annual regulatory disclosure rather than a fresh business trigger, so it is unlikely to cause an immediate stock reaction on its own. However, it reinforces PPL's improving financial health and ESG profile, which may support long-term investor confidence and appeal to sustainability-focused funds.